To hear about similar clinical trials, please enter your email below
Trial Title:
Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
NCT ID:
NCT00757263
Condition:
Ovarian Cancer
Conditions: Official terms:
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Conditions: Keywords:
ovarian epithelial cancer
ovarian germ cell tumor
ovarian sarcoma
ovarian stromal cancer
Study type:
Observational
Overall status:
Unknown status
Intervention:
Intervention type:
Genetic
Intervention name:
polymorphism analysis
Intervention type:
Other
Intervention name:
laboratory biomarker analysis
Intervention type:
Other
Intervention name:
questionnaire administration
Summary:
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors learn more about changes that occur in DNA and identify biomarkers related to
cancer.
PURPOSE: This study is looking at genetic susceptibility for cancer and interactions
between genes and the environment in patients with ovarian cancer.
Detailed description:
OBJECTIVES:
- To obtain epidemiological information and biological material on a population-based
series of ovarian cases.
- To define the proportion of ovarian cancer incidence attributable to mutations in
known predisposing genes (e.g., BRCA1 and BRCA2).
- To determine the risk associated with predisposing mutations by examining the cancer
risks in relatives of patients who are shown to be carriers.
- To examine the effect of nongenetic risk factors in mutation carriers.
- To determine the pathological and clinical characteristics of ovarian cancers
occurring in BRCA1/2 mutation carriers as compared with that in noncarriers.
- To establish whether mutations at other loci may predispose to ovarian cancer by
comparing the frequency of alterations in ovarian cancer patients with that in
cancer-free controls identified through the European Prospective Investigation of
Cancer (EPIC) study.
OUTLINE: This is a multicenter study.
Patients complete an epidemiological questionnaire. The questionnaire will request
identifying information on the patient's first-degree relatives.
Blood samples are collected from patients. DNA is extracted from these blood samples and
from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL as
well as from additional controls through the European Prospective Investigation of Cancer
(EPIC) study (a population based study of diet and health based in Norfolk, East Anglia).
DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.
In addition to the ovarian cancer patients recruited for this study, patients with
breast, endometrial, prostate, colorectal, bladder, kidney, pancreatic, brain and
esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following
related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-ENDOMETRIAL,
MREC-SEARCH-PROSTATE, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-CANCER.
Criteria for eligibility:
Criteria:
DISEASE CHARACTERISTICS:
- Diagnosis of ovarian cancer within the past 5 years
- Identified through the East Anglia, Stoke and West Midlands Cancer Registries
serving any of the following geographic regions of the United Kingdom:
- East Anglia
- Oxford
- Trent
- West Midlands
PATIENT CHARACTERISTICS:
- Identified by the patient's general practitioner as fit to contact for this study
- No serious mental illness or retardation
PRIOR CONCURRENT THERAPY:
- Not specified
Gender:
All
Minimum age:
18 Years
Maximum age:
74 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Cambridge Cancer Research UK
Address:
City:
Cambridge
Zip:
CB1 8RN
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Contact Person
Phone:
44-122-374-0166
Email:
paul.pharoah@srl.cam.ac.uk
Start date:
February 2008
Lead sponsor:
Agency:
Cancer Research UK
Agency class:
Other
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00757263
